Personalis, Inc. (PSNL) AI Stock Analysis

Personalis, Inc. is a global leader in cancer genomics, providing comprehensive sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research initiatives. Its flagship NeXT Platform supports advanced data analysis of tumor and immune microenvironments from tissue or plasma samples. Key offerings include ImmunoID Next, NeXT Liquid Biopsy, and NeXT Personal for personalized tumor tracking, as well as the NeXT Dx Test for genomic cancer profiling. The company also uses its ACE platform for neoantigen prediction, biomarker discovery, and novel drug target identification. It serves biopharmaceutical companies, universities, non-profits, and government entities, collaborating with institutions such as Mayo Clinic and Moores Cancer Center.

Between FY2021 and FY2025, annual revenue fluctuated, falling from $85.5M in FY2021 to $65.0M in FY2022 before rising to $84.6M in FY2024 and declining 17.7% to $69.6M in FY2025. This yielded a 5-year revenue CAGR of -2.4%. Profitability has remained negative across all reported years, with FY2025 operating margin at -126.4% and net income of -$81.3M. In the trailing twelve months ended June 30, 2026, revenue stood at $69.7M with an operating margin of -150.2% and EPS of -$1.09. However, quarterly revenue growth showed an acceleration of 30.0% year-over-year in the quarter ended June 30, 2026.

As of June 30, 2026, Personalis reported $212.7M in cash and short-term investments and $38.0M in total debt, resulting in net cash of $174.7M. The current ratio stood at 5.28, and the debt-to-equity ratio was 0.16 on shareholders' equity of $235.2M. The company continues to generate negative cash flow, recording operating cash flow of -$74.9M and free cash flow of -$79.5M in FY2025. Capital expenditures totaled $4.5M in FY2025, and share count expanded 135.3% over the prior five years.

Personalis trades at a price-to-sales multiple of 24.0x and an enterprise value-to-revenue multiple of 22.6x, compared to a median price-to-sales of 4.1x for its US-listed Healthcare peers. Its price-to-book ratio is 7.4x. Over the past year, the stock returned 52.2%, outperforming the S&P 500 (SPY) return of 16.8%. Over a five-year horizon, however, PSNL delivered a return of -21.5%, lagging the S&P 500 return of 83.0%. The stock carries a beta of 2.32.

Wall Street analyst coverage consists of 1 Strong Buy, 0 Buy, 4 Hold, 0 Sell, and 0 Strong Sell ratings. The mean price target is $15.17, which sits 3.1% below the last close of $15.65. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $84.3M and an EPS of -$1.08. For FY2027, 7 analysts project revenue to reach $110.2M with EPS of -$0.94. Personalis beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 3, 2026.

This page is an AI-written research summary of Personalis, Inc. (PSNL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: PSNL income statement, PSNL balance sheet, PSNL key metrics, PSNL analyst forecast, PSNL chart. See the PSNL stock overview for the latest quote and news.